1-13 of 13
Rebecca J. Nagy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Steven B. Maron, Walid Chatila, Henry Walch, Joanne F. Chou, Nicholas Ceglia, Ryan Ptashkin, Richard Kinh Gian Do, Viktoriya Paroder, Neeta Pandit-Taskar, Jason S. Lewis, Tiago Biachi De Castria, Shalom Sabwa, Fiona Socolow, Lara Feder, Jasmine Thomas, Isabell Schulze, Kwanghee Kim, Arijh Elzein, Viktoria Bojilova, Matthew Zatzman, Umesh Bhanot, Rebecca J. Nagy, Jeeyun Lee, Marc Simmons, Michal Segal, Geoffrey Yuyat Ku, David H. Ilson, Marinela Capanu, Jaclyn F. Hechtman, Taha Merghoub, Sohrab Shah, Nikolaus Schultz, David B. Solit, Yelena Y. Janjigian
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3633–3640.
https://doi.org/10.1158/1078-0432.CCR-22-3769
Published: 15 September 2023
View articletitled, Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Open the PDF for Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer in another window
Includes: Supplementary data
Journal Articles

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K. Lennerz, Adam Langenbucher, Jessica J. Lin, Marguerite M. Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A. Adams, Beow Y. Yeap, Emily Chin, Andrew Do, Hetal D. Marble, Sara E. Stevens, Subba R. Digumarthy, Ashish Saxena, Rebecca J. Nagy, Cyril H. Benes, Christopher G. Azzoli, Michael S. Lawrence, Justin F. Gainor, Alice T. Shaw, Aaron N. Hata
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2535–2545.
https://doi.org/10.1158/1078-0432.CCR-19-3906
Published: 01 June 2020
View articletitled, MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Open the PDF for MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

Charu Aggarwal, Jeffrey C. Thompson, Austin L. Chien, Katie J. Quinn, Wei-Ting Hwang, Taylor A. Black, Stephanie S. Yee, Theresa E. Christensen, Michael J. LaRiviere, Benjamin A. Silva, Kimberly C. Banks, Rebecca J. Nagy, Elena Helman, Abigail T. Berman, Christine A. Ciunci, Aditi P. Singh, Jeffrey S. Wasser, Joshua M. Bauml, Corey J. Langer, Roger B. Cohen, Erica L. Carpenter
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2354–2361.
https://doi.org/10.1158/1078-0432.CCR-19-3663
Published: 15 May 2020
View articletitled, Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Open the PDF for Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma

Steven B. Maron, Leah M. Chase, Samantha Lomnicki, Sara Kochanny, Kelly L. Moore, Smita S. Joshi, Stacie Landron, Julie Johnson, Lesli A. Kiedrowski, Rebecca J. Nagy, Richard B. Lanman, Seung Tae Kim, Jeeyun Lee, Daniel V.T. Catenacci
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (23): 7098–7112.
https://doi.org/10.1158/1078-0432.CCR-19-1704
Published: 02 December 2019
View articletitled, Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Open the PDF for Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J. Lin, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (22): 6662–6670.
https://doi.org/10.1158/1078-0432.CCR-19-1436
Published: 15 November 2019
View articletitled, Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Open the PDF for Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity in another window
Includes: Supplementary data
Journal Articles

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Giulia Siravegna, Andrea Sartore-Bianchi, Rebecca J. Nagy, Kanwal Raghav, Justin I. Odegaard, Richard B. Lanman, Livio Trusolino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (10): 3046–3053.
https://doi.org/10.1158/1078-0432.CCR-18-3389
Published: 15 May 2019
View articletitled, Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Open the PDF for Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric H. Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler, Jr, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 277–289.
https://doi.org/10.1158/1078-0432.CCR-18-1544
Published: 03 January 2019
View articletitled, Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Open the PDF for Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Magda Bahcall, Mark M. Awad, Lynette M. Sholl, Frederick H. Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V. Ivanova, Giulia C. Leonardi, Bryan C. Ulrich, Cloud P. Paweletz, Paul T. Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J. Nagy, Richard B. Lanman, Marzia Capelletti, Emily S. Chambers, Amanda J. Redig, Paul A. VanderLaan, Daniel B. Costa, Yu Imamura, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5963–5976.
https://doi.org/10.1158/1078-0432.CCR-18-0876
Published: 03 December 2018
View articletitled, Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Open the PDF for Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

Justin I. Odegaard, John J. Vincent, Stefanie Mortimer, James V. Vowles, Bryan C. Ulrich, Kimberly C. Banks, Stephen R. Fairclough, Oliver A. Zill, Marcin Sikora, Reza Mokhtari, Diana Abdueva, Rebecca J. Nagy, Christine E. Lee, Lesli A. Kiedrowski, Cloud P. Paweletz, Helmy Eltoukhy, Richard B. Lanman, Darya I. Chudova, AmirAli Talasaz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3539–3549.
https://doi.org/10.1158/1078-0432.CCR-17-3831
Published: 31 July 2018
View articletitled, Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Open the PDF for Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies in another window
Includes: Supplementary data
Journal Articles

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough, Stefanie A. Mortimer, James V. Vowles, Reza Mokhtari, David R. Gandara, Philip C. Mack, Justin I. Odegaard, Rebecca J. Nagy, Arthur M. Baca, Helmy Eltoukhy, Darya I. Chudova, Richard B. Lanman, AmirAli Talasaz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3528–3538.
https://doi.org/10.1158/1078-0432.CCR-17-3837
Published: 31 July 2018
View articletitled, The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Open the PDF for The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

Benedito A. Carneiro, Sahithi Pamarthy, Ami N. Shah, Vinay Sagar, Kenji Unno, HuiYing Han, Ximing J. Yang, Rubens B. Costa, Rebecca J. Nagy, Richard B. Lanman, Timothy M. Kuzel, Jeffrey S. Ross, Laurie Gay, Julia A. Elvin, Siraj M. Ali, Massimo Cristofanilli, Young K. Chae, Francis J. Giles, Sarki A. Abdulkadir
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2732–2739.
https://doi.org/10.1158/1078-0432.CCR-18-0332
Published: 14 June 2018
View articletitled, Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
Open the PDF for Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib in another window
Includes: Supplementary data
Journal Articles

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Giovanna Rossi, Zhaomei Mu, Alfred W. Rademaker, Laura K. Austin, Kimberly S. Strickland, Ricardo Lima Barros Costa, Rebecca J. Nagy, Vittorina Zagonel, Timothy J. Taxter, Amir Behdad, Firas H. Wehbe, Leonidas C. Platanias, William J. Gradishar, Massimo Cristofanilli
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (3): 560–568.
https://doi.org/10.1158/1078-0432.CCR-17-2092
Published: 31 January 2018
View articletitled, Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer
Open the PDF for Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients

Yuebi Hu, Ryan S. Alden, Justin I. Odegaard, Stephen R. Fairclough, Ruthia Chen, Jennifer Heng, Nora Feeney, Rebecca J. Nagy, Jayshree Shah, Bryan Ulrich, Martin Gutierrez, Richard B. Lanman, Judy E. Garber, Cloud P. Paweletz, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7351–7359.
https://doi.org/10.1158/1078-0432.CCR-17-1745
Published: 30 November 2017
View articletitled, Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
Open the PDF for Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients in another window
Includes: Supplementary data